Abstract
Colorectal cancer (CRC) is a highly aggressive and life-threatening malignancy that metastasizes in ~50% of patients, posing significant challenges to patient survival and treatment. Fatty acid (FA) metabolism regulates proliferation, immune escape, metastasis, angiogenesis, and drug resistance in CRC. FA metabolism consists of three pathways: de novo synthesis, uptake, and FA oxidation (FAO). FA metabolism-related enzymes promote CRC metastasis by regulating reactive oxygen species (ROS), matrix metalloproteinases (MMPs), angiogenesis and epithelial-mesenchymal transformation (EMT). Mechanistically, the PI3K/AKT/mTOR pathway, wnt/β-catenin pathway, and non-coding RNA signaling pathway are regulated by crosstalk of enzymes related to FA metabolism. Given the important role of FA metabolism in CRC metastasis, targeting FA metabolism-related enzymes and their signaling pathways is a potential strategy to treat CRC metastasis.
Similar content being viewed by others
Facts
-
FA metabolism-related enzymes profoundly affect various physiological processes of CRC metastasis, and precisely targeting FA metabolism-related enzymes is a new direction of cancer therapy.
-
FA metabolism-related enzymes promote CRC metastasis by regulating reactive ROS, MMPs, angiogenesis, and EMT.
-
FA metabolism-related enzymes are involved in various pathways in CRC metastasis, including PI3K/AKT/mTOR pathway, wnt/β-catenin pathway, and non-coding RNA signaling pathway. An imbalance of any enzyme will affect CRC metastasis.
Open questions
-
What is the role of FA metabolism in tumor progression?
-
How do FA metabolism-related enzymes play a regulatory role in colorectal cancer metastasis?
-
What are the clinical treatment drugs for CRC metastasis?
Introduction
Colorectal cancer (CRC) is the cause of the second largest number of cancer deaths globally, with incidence rates continuing to rise in developed countries [1]. By 2024, ~152,810 cases of CRC are expected to be diagnosed in the United States (7.6% of new cancer cases in the United States) and ~53,010 deaths (8.6% of cancer deaths in the United States) [2]. Unfortunately, the global incidence of CRC is expected to increase to 2.5 million cases by 2052 [3]. Recent studies have shown that the incidence and mortality of CRC not only affect the elderly but also increase in young people [4]. Multiple risk factors such as genetics, environment, and poor living habits affect the occurrence and development of CRC [5, 6].
Distant metastasis is the main cause of CRC-related death, and the liver is the most common organ affected by CRC metastasis [7]. In clinical patients, 50% of CRC eventually develop liver metastasis [8]. The second most common organ involved in the distant metastasis of CRC is the lung [9, 10]. Recent studies have shown that 10-15% of CRC develop lung metastases, and the 5-year survival rate of patients diagnosed with metastatic CRC is less than 20% [11,12,13].
Abnormal alterations in energy metabolism have become important markers of cancer, and fatty acid (FA) metabolism is generally enhanced at different stages of tumor progression [14]. To metastasize, tumor cells use FA metabolism to promote different steps of the metastasis cascade, from the initiation of metastasis to the promotion of cell colonization growth after metastasis [15]. FA-related metabolic and structural adaptations in tumors include changes in lipid membrane composition to invade other sites, overcoming cell death mechanisms, and promoting lipolysis and anabolism for energy and oxidative stress protection purposes [16].
Studies have shown that obesity is a risk factor for 13 types of cancer, including CRC, and tumor cells can meet their energy needs for rapid proliferation through lipid metabolism [17,18,19]. Lipid biology includes FA metabolism, fat and cholesterol homeostasis, which are important processes in tumor metastasis [20]. FA accumulation is more significant in metastatic tumors than in primary tumors. In lipid-rich lymph nodes, metastatic tumor cells tend to use fatty acids as the primary fuel for energy production [21]. In ovarian cancer, adipocytes promote tumor growth by supplying FA to cancer cells, which in turn promote metastasis [22]. The energy storage/production hypothesis should be the most important mechanism of tumor metastasis.
Therefore, this review focuses on recent advances in understanding the relationship between FA metabolism and CRC metastasis.
A systematic literature search of PubMed was conducted to identify articles published between January 1, 2014, and January 1, 2024, focusing on the following areas of interest: “Colorectal cancer”, “metastasis”, and “fatty acid metabolism”. Boolean operators are used to create targeted search strategies. After selecting the keywords, a search was performed in PubMed “All Fields”.
Structure and functions of FA
FA consisting of carboxyl groups and hydrocarbon chains of varying carbon lengths and unsaturation are involved in cell signaling, regulation of immune responses, and maintenance of homeostasis in the internal environment [23,24,25]. FA can be divided into saturated fatty acids (SFAs) without double bonds, monounsaturated fatty acids (MUFAs) containing one double bond, and polyunsaturated fatty acids (PUFAs) containing at least two double bonds according to the number of double bonds [26]. Palmitic acid (PA) is a kind of SFAs. PA has anti-inflammatory, anti-oxidation, and immune-enhancing effects. PA induces tumor cell apoptosis, inhibits tumor cell proliferation, inhibits metastasis and invasion, enhances sensitivity to chemotherapy, and improves immune function [27]. Oleic acid is one of the most abundant MUFAs, regulating cell membrane fluidity, receptors, intracellular signaling pathways, and gene expression [28, 29]. The PUFA family includes α-linolenic acid, stearic acid, eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid, which can provide energy for the body, inhibit the inflammatory response, and regulate body metabolism [30]. FA exists in various cellular structures and regulates biochemical activities of normal cells, including the generation and regulation of biofilm fluidity, as a second messenger of signaling pathways, and as a mode of energy storage [31,32,33]. Normal cells mainly take up exogenous FA, while tumor cells promote FA production [34]. Therefore, understanding the mechanisms by which FA regulates CRC metastasis are critical for the prevention and treatment of CRC.
Mechanism of FA metabolism-regulating tumor metastasis
FA metabolism regulates matrix metalloproteinases (MMPs)
MMPs are the proteases that remodel and degrade extracellular matrix [35]. MMPs are released by various connective tissues and cells, including fibroblasts, osteoblasts, endothelial cells, macrophages, neutrophils, and lymphocytes [36]. Multiple studies have shown that FA metabolism is involved in various pathological processes by regulating MMPs, such as promoting tumor angiogenesis, invasion, and metastasis [37]. For example, microRNA-199a-3p activated the phosphatidylinositol-3-kinase/ (PI3K)/AKT signaling pathway and upregulated the expression of MMP2 by regulating the expression of stearoyl-CoA desaturase 1 (SCD1), thereby inhibiting the metastasis of nasopharyngeal carcinoma [38]. In CRC, sterol regulatory element-binding protein 1 (SREBP1) promoted tumor cell metastasis by activating the nuclear factor-κB (NF-κB)/MMP7 axis [39] (Fig. 1).
FA metabolism regulates angiogenesis
Angiogenesis depends on an adequate blood supply and is an important cause of tumor growth and metastasis [40]. In animal models of xenografted tumors, the tumor microenvironment is hypoxic when the diameter is greater than 2 mm. As a result, tumors need to form new blood vessels to provide oxygen and essential nutrients [41,42,43]. Vascular overgrowth and upregulation of pro-angiogenic factors promote tumor metastasis, the degree of which is affected by pro-angiogenic factors [44]. FA metabolism can promote tumor metastasis by regulating angiogenesis. Gao et al. demonstrated that SREBP1 overexpression promoted angiogenesis in endothelial cells, which in turn promoted the invasion and metastasis of CRC cells [45] (Fig. 1).
FA metabolism regulates epithelial-mesenchymal transition (EMT)
EMT is a complex cellular process executed by EMT-activating transcription factors, mainly the zinc finger protein SNAI, Twist‐related protein and zinc finger E‐box‐binding homeobox families [46,47,48]. In solid tumors, EMT plays a role in tumorigenesis, invasion, metastasis, cancer stemness and drug resistance [49]. FA metabolism is widely confirmed to be involved in the process of EMT. Du et al. showed that downregulation of miR-130b promoted the expression of peroxisome proliferators-activated receptors gamma (PPAR-γ), which subsequently inhibited EMT in hepatocellular carcinoma [50]. Long-chain acyl-coenzyme A synthases family member 3 Gene (ACSL3) stimulated EMT of CRC cells, providing fuel for tumor cell invasion and distant metastasis [51] (Fig. 1).
FA metabolism regulates reactive oxygen species (ROS)
ROS as a normal cell signaling molecules of biological processes [52]. ROS includes oxygen radicals, such as superoxide anion radicals (O2−) and hydroxyl radicals (OH), and non-radical oxidants, such as hydrogen peroxide (H·2O2) and singlet oxygen (1O2) [53]. ROS acts as signaling molecules in cancer, leading to cell growth, metastasis and angiogenesis [54]. In ovarian cancer, increased ROS production and activation of the AKT/mammalian target of rapamycin (mTOR) signaling pathway were involved in the upregulation of SREBP1 and SREBP2, which promoted cell growth and metastasis [55] (Fig. 1).
FAO regulates tumor metastasis
FAO is a whole process involving FA activation, transporting, β oxidation and TCA cycle. FAO mainly focuses on β-oxidation, and the important site of β-oxidation is mitochondria, which generates acetyl-CoA through a series of reactions and enters TCA cycle coupled oxidative phosphorylation to produce ATP and reduced Coenzyme II, providing corresponding energy and reducing power for cell growth. CPT1, located in the outer membrane of mitochondria, catalyzes the esterification of long-chain acyl groups with carnitine and is a key rate-limiting step of FAO, mediating cellular FAO [56]. Studies have shown that significantly elevated expression of transcriptional coactivator yes-associated protein (YAP) can mediate the production of FAO in tumor cells during lymph node metastasis, and this metabolism contributes to the metastasis of tumor cells [20]. Nuclear Receptor Nur77 promotes FAO in glucose starvation and promotes melanoma metastasis by protecting the key FAO enzyme TPβ from oxidative inactivation [57]. FAO helps AMPK regulate NADPH homeostasis in cancer cells, and FA β-oxidation promotes cancer cell survival under energy stress, thus promoting CRC metastasis [58, 59] (Fig. 1).
PUFA biosynthetic pathway and ferroptosis
The ferroptosis was first proposed by Dixon et al. in 2012. Ferroptosis refers to the type of iron-dependent regulatory cell death induced by lipid peroxidation in cell membranes [60]. The link between PUFA and ferroptosis is that PUFAs are particularly prone to oxidation, which leads to the formation of lipid peroxides, resulting in membrane rupture and eventual cell death. Interestingly, the balance between omega-3 polyunsaturated fatty acids and omega-6 polyunsaturated fatty acids could also play a role in ferroptosis. Omega-3 polyunsaturated fatty acids are more prone to oxidation and may promote ferroptosis, whereas omega-6 polyunsaturated fatty acids can be converted into proinflammatory molecules that prevent ferroptosis by activating antioxidant pathways [61]. ELOVL2, ELOVL5, FADS1, and FADS2, these enzymes play an important role in the PUFA synthesis pathway and also play an important role in ferroptosis [62, 63]. The decreased expression of ELOVL5 and FADS1 in gastric cancer and CRC cells suggests that these two enzymes can be used as predictive markers for ferroptosis-mediated cancer therapy [62] (Fig. 1).
The role of FA metabolism-related enzymes in CRC metastasis
In recent years, the role of FA metabolism-related enzymes in CRC metastasis has been extensively studied, and different enzymes promote metastasis through unique mechanisms involving the MMP, EMT, angiogenesis, and ATP production (Table 1). The molecular mechanism of FA metabolism-related enzymes regulating CRC metastasis will be elucidated in this review.
The role of FA synthesis-related enzymes in CRC metastasis
SREBP
SREBF contains two homologous genes and three isoforms: SREBP1a and SREBP1c, which are encoded by the SREBF1 gene, and SREBP2, which is encoded by the SREBF2 gene [64]. SREBF1 mainly regulates the synthesis of FA and triglyceride (TG), while lipoprotein uptake and de novo cholesterol synthesis are mainly regulated by SREBF2 [65]. In the process of FA metabolism, the expression of various FA metabolism-related genes is regulated by SREBP1, including acetyl-CoA carboxylase (ACC), fatty acid synthetase (FASN), and SCD1 [66]. Multiple studies have shown that SREBP1 promotes CRC metastasis by regulating downstream FA metabolism-related enzymes [45]. In addition, SREBP1 not only regulates the synthesis of various lipids in cells but also plays a key role in the occurrence and development of malignant tumors. SREBP1 promotes CRC metastasis by influencing ROS, increasing MMPs expression, and angiogenesis. Gao et al. found that overexpression of SREBP1 in HT29 cells promoted endothelial cell angiogenesis, increased ROS and MMP7 expression, and further promoted the invasion and metastasis of CRC cells [45]. SREBP1 also promoted the invasion of CRC cells by increasing ROS to activate NF-κB/MMP7 axis [39]. Therefore, the development of targeted drugs against SREBP1 may be a new direction for the treatment of CRC metastasis.
ATP citrate lyase (ACLY)
The first key enzyme in de novo lipogenesis is ACLY, which is an important bridge connecting cellular glucose and lipid metabolism [67]. Citrate enters the cytoplasm from mitochondria and is catalyzed by ACLY to generate Ac-CoA, which in turn is an important raw material for FA synthesis. Therefore, changes in energy metabolism in tumor cells, increased glucose uptake and increased glycolytic flux accelerate the increase in citrate yield, ultimately promoting cellular FA synthesis [68, 69]. ACLY is related to the migration and invasion ability of CRC cells by Pearson correlation analysis [70]. Abnormal expression of ACLY contributes to enhancing the drug resistance of metastatic CRC [71]. In addition, Qiao et al. demonstrated that homeobox A13 (HOXA13) promoted CRC metastasis by transactivating ACLY and insulin-like growth factor receptor (IGF-1R) [72].
ACSL
ACSL regulates CRC metastasis mainly by affecting EMT. In mammals, the ACSL family comprises five members, ACSL1 and ACSL3-6 [73]. In the liver, heart, adipose, and muscle, ACSL1 is widely expressed [74]. It acts as a key enzyme in FA uptake, FAO, and TG synthesis [73]. ACSL3 promotes the production of ATP and reduces nicotinamide adenine dinucleotide phosphate (NADPH), stimulate EMT and metastasis in CRC cells [51]. Current studies have shown that the downregulation of ACSL can predict the prognosis of CRC with metastasis at an early stage, and targeting ACSL3 to affect EMT provides new targets and ideas for clinical treatment.
Acetyl-CoA carboxylase (ACC)
ACC (including ACC1 and ACC2), a key enzyme in FA synthesis, regulates the adipogenesis, metastasis, and apoptosis of CRC cells. The first rate-limiting enzyme in the de novo FA synthesis pathway is ACC1, which is located in the cytoplasm [75]. ACC2 produces Malonyl-CoA during de novo FA synthesis [76]. Malonyl-CoA also plays an important role in FA catabolism as a direct substrate for FA synthesis [68]. It has been widely demonstrated that the role of AMP-activated protein kinase (AMPK) signaling in the growth, proliferation, angiogenesis, metastasis, and invasion of CRC. ACC is a target molecule of AMPK, and phosphorylation of AMPK regulates ACC activity [77]. On the other hand, regenerating islet-derived 4 (REG4) induces the degradation of ACC1 or the ACLY proteasome, while lymph node and distant metastasis, and the tumor-lymph node metastasis stage are negatively correlated with REG4 overexpression[78].
FASN
FASN regulates CRC metastasis mainly by affecting ATP production. As a key enzyme in FA synthesis, FASN is significantly elevated in cancer associated fibroblasts and plays a key role in the growth and survival of lipogenic phenotype tumors [79]. FASN is a large multienzyme complex with a monomeric protein size of ~270 kDa [80]. There are two subtypes of FASN (FASN1 and FASN2), with FASN1 found in fungi and animals and FASN2 found in prokaryotes and plants. FASN converts excess carbohydrates into FA, which is esterified by other enzymes into stored lipids that provide energy through oxidation when needed by the body [81]. Clinical studies have shown that FASN is significantly expressed in CRC [49]. FSCN1 knockdown reduced the expression of FASN and SCD1, SFA was converted to MUFA via SCD1, and FASN chains were elongated to increase the production of ATP, thereby promoting CRC metastasis [82, 83].
SCD
SCD promotes ATP production, which provides the necessary conditions for rapid tumor growth and metastasis initiation. SCD is a central lipogenic enzyme that catalyzes the synthesis of MUFAs from SFA, palmitate, and stearate [84]. To date, a total of four mouse SCD subtypes (1 to 4) and two human SCD subtypes (1 and 5) have been identified. Bioinformatics analysis revealed that high expression of SCD1 was associated with invasive and metastatic phenotypes of CRC [85, 86]. Ferroptosis is critical for CRC progression due to the redox imbalance of tumor cells, characterized by lipid peroxidation. Studies have shown that inhibition of SCD1 partially eliminates the resistance of Nodal growth differentiation factor (Nodal) overexpressing cells to ferroptosis, thus promoting the survival and metastasis of CRC cells [87]. Nodal overexpression induces MUFA synthesis and increases the level of unsaturated lipids. Mechanistically, the transcription of SCD1 is upregulated by Smad 2/3 signaling when Nodal is overexpressed [87]. In addition, SCD1 converts SFAs into MUFAs, and its chain is lengthened to increase ATP production, thereby promoting CRC metastasis [82]. In conclusion, targeting SCD1 may become a novel therapeutic strategy for the treatment of CRC metastasis.
The role of FA uptake-related enzymes in CRC metastasis
CD36
CD36 is a member of scavenger receptor family B and is expressed on the surface of various cells, such as adipocytes, hepatocytes, and cardiomyocytes [88]. CD36 is involved in tumor pathogenesis by regulating the mitochondrial gene PPAR [89]. High expression of CD36 in CRC tissues is associated with malignant transformation and predicts poor survival of CRC based on bioinformatics analysis [90]. CD36 allows the uptake of lipids from the extracellular microenvironment by cells and promotes ATP production, which stimulates tumor progression and metastasis [91, 92]. On the other hand, CD36 plays an important regulatory role in CRC metastasis by upregulating MMP28 [93] (Fig. 2).
Fatty acid binding protein (FABP)
FABP is a family of multifunctional proteins involved in FA metabolism. FABP is classified into 12 subtypes according to different tissue sources [94]. In lipid metabolism, long-chain FAs bind to FABP to improve FA solubility and facilitate FA transport to cell or mitochondrial membranes [95, 96]. At present, the expression level of FABP in CRC is still inconclusive. Based on ONCOMINE and GEPIA2 analyses, Prayugo et al. found that the expression of the FABP1 and FABP6 genes was significantly increased in CRC, and different tumor stages of CRC were related to the expression levels of FABP3 and FABP4 mRNA [97, 98]. Consistent with Prayugo’s analysis results, recent studies have shown that FABP4 is more expressed in tumor node metastasis stages I-II than III-IV and is involved in metabolic reprogramming, tumor differentiation, and metastasis [99, 100]. However, FABP1 was downregulated in CRC tissues according to the single cell transcriptome analysis of epithelial cells from 272 CRC and 160 normal epithelial cells [97]. This finding further suggested that FABP may play dual roles in CRC progression. Mechanistic studies have shown that FABP5 expression is upregulated in metastatic CRC cells by continuously promoting DNA demethylation and activation of the NF-κB pathway, which in turn regulates NF-κB activity through IL-8 production [101]. Further study on the specific mechanism of FABP in CRC will help to provide new strategies for targeted therapy in CRC.
The role of FAO-related enzymes in CRC metastasis
PPAR
PPAR has three isoforms, α, β and γ. PPAR-α is highly expressed in the liver and is involved in physiological activities such as energy metabolism, oxidative stress, and inflammation. PPAR-β plays a role in inhibiting the inflammatory response. PPAR-γ is widely expressed in various adipose tissues and participates in lipid metabolism [102, 103]. In mice, DNMT1-mediated Cdkn1a (P21) methylation and PRMT6-mediated increases in Cdkn1b (P27) methylation lead to PPAR-α reduced and promote colon tumorigenesis and growth [104]. In CRC, the protein tyrosine phosphatase receptor type O gene (PTPRO) promotes the expression of FAO enzymes by upregulating PPAR-α, thereby promoting tumor metastasis [105]. The Nanog promoter in CRC cells directly binds to PPAR-β to induce Nanog expression, which in turn induces colon cancer stem cell (CSC) expansion and CRC liver metastasis [106].
Carnitine palmitoyl transferase (CPT)
CPT is a key FAO enzyme that is present in the inner membrane of mitochondria. The CPT family consists of CPT1 and CPT2. CPT1 is located outside the mitochondrial membrane and includes three tissue-specific isoforms. CPT2 is a widely distributed protein located in the inner mitochondrial membrane [107, 108]. Long-chain FA must be converted to acyl-carnitines before entering the mitochondrial matrix for oxidation [108]. Malonyl-CoA (a component of ACC) blocks the activity of CPT1, FAO is accelerated when ACC is inhibited. Previous studies have shown that phosphorylation of ACC reduces tumor cell proliferation by enhancing FA degradation [83, 109]. The expression level of CPT1A was found to be reduced in peritoneal metastatic CRC [110]. In addition, FAO activation mediated by CPT1A and CPT1C increases the metastatic capacity of CRC [111, 112].
Signaling pathways regulating FA metabolism in CRC metastasis
PI3K/AKT/mTOR signaling pathway
The PI3K/AKT/mTOR signaling pathway promotes tumor cell proliferation, metabolism, and angiogenesis [113]. In recent years, it has been found that the PI3K/AKT/mTOR signaling pathway promotes CRC metastasis by regulating FA synthesis-related enzymes. Insulin-like growth factor 1 (IGF1) upregulates HOXA13 expression via the PI3K/AKT signaling pathway. HOXA13 promotes CRC metastasis through transactivation of ACLY and IGF1R [72]. Silencing of PTPRO enhances the expression of SREBP1 and its target lipogenic enzyme ACC1 by activating the AKT/mTOR signaling pathway, thus promoting adipogenesis, cell growth, and liver metastasis [105]. In addition, FA metabolism reversely activates the PI3K/AKT/mTOR signaling pathway, forming a loop of positive feedback. FABP4 overexpression regulates the increase of FAs and activates AKT pathway and EMT, thereby promoting the migration and invasion of CRC cells [114] (Fig. 3).
Wingless (Wnt)/β-catenin signaling pathway
Wnt signaling pathway includes nonclassical pathway independent of β-catenin and classical pathway known as Wnt/β-catenin pathways [115]. The Wnt/β-catenin signaling pathway is a conserved signal transduction axis involved in various physiological processes such as proliferation, differentiation, apoptosis, migration, invasion, and tissue homeostasis [116]. β-catenin is a key mediator of Wnt signal transduction and is present in multiple subcellular locations, including adhesive junctions, where it helps stabilize cell-to-cell contact. Its levels in the cytoplasm are controlled by processes that regulate protein stability and are involved in transcriptional regulation and chromatin interactions in the nucleus [117]. Hai et al. found that FASN expression was positively correlated with Wnt signaling-related gene expression, and genetic perturbation indicated that FASN knockdown inhibited cell migration and invasion of CRC cell lines [118]. In addition, miR-20 activated the Wnt/β-catenin signaling pathway and upregulated FA synthesis, ultimately promoting the proliferation and migration of metabolic CRC cells [119] (Fig. 3).
Noncoding RNA
Noncoding RNA is a group of functional RNA that cannot be transcribed into proteins but are involved in various biological processes that regulate gene transcription and translation. Noncoding RNA accounts for 98% of the whole genome transcripts, including microRNA (miRNA), long-stranded non-coding RNA (lncRNA), small interfering RNA (siRNA), and circular RNA (circRNA) [120]. The expression level of miRNA-27a-3p is negatively correlated with CD36 in CRC metastatic [79, 121]. Peng et al. demonstrated that FASN and ACC1 were regulated by lncRNA-TSPEAR-AS1 to promote CRC progression [122] (Fig. 3). circCAPRIN1 interacts with signal transducer and activator of transcription 2 (STAT2) to increase the expression of ACC1 and promote tumor progression and lipid synthesis of CRC cells [123] (Fig. 3). In CRC liver metastasis, circNOLC1 interacts with Zinc-α2-glycoprotein 1 (AZGP1) to activate mTOR/SREBP1 signal transduction and the oxidative pentose phosphate pathway [124] (Fig. 3).
MAPK signaling pathway
MAPK signaling pathway is a classical intracellular signal transduction system that controls a variety of cellular processes, such as cell differentiation, proliferation, and apoptosis [125]. MAPK consists of three major families: extracellular signal-regulated kinase 1/2 (ERK1/2), c-Jun N-terminal kinase (JNK), and p38. These families play an important role in CRC carcinogenic effects [126]. PTPRO attenuation activates P38/ERK signaling pathway, resulting in decreased expression of PPARα and ACOX1, thereby reducing the rate of FAO and promoting CRC metastasis [105]. RPL21 and lysosomal associated membrane protein 3 (LAMP3) promote CRC cell metastasis by activating the FAK/paxillin/ERK signaling pathway, thereby increasing the formation of immature FA [127] (Fig. 3).
Therapeutic agents for FA metabolism in CRC metastasis
Echinoside is a major phenylethanol glycoside structural compound identified in Huangzu granules that inhibits the invasion and metastasis of CRC and prolongs the disease-free survival of patients [128]. Pterostilbene (PTS) inhibits cell migration by downregulating FABP5 gene expression thus alleviating obesity-induced CRC metastasis [129]. Cerulenin is a natural FA synthase inhibitor that can prevent and delay CRC liver metastasis [119]. Inulin, cellulose, and their mixtures inhibit CRC metastasis by regulating the intestinal microbiota, producing short-chain fatty acids, and inhibiting EMT [130]. Mangiferin inhibits tumor growth, metastasis, and angiogenesis by targeting mitochondrial redox enzymes and FAO metabolic signaling pathways [131]. Resveratrol is a polyphenolic compound with antioxidant, anti-inflammatory, apoptosis-inducing, and anti-angiogenic properties. It plays an important role in the treatment of CRC [132, 133] (Table 2).
Conclusion
In summary, FA metabolism is an important trigger of CRC metastasis. FA metabolism-related enzymes (SREBP1, ACLY, ACSL, ACC, FASN, SCD1, etc.) regulate ROS, EMT, MMPs, and angiogenesis in tumor cells, thereby promoting CRC metastasis. Having learned the important role of FA metabolism in CRC metastasis, an understanding of its regulatory mechanisms will allow researchers the opportunity to develop new therapeutic approaches. These may include :(1) targeting FA metabolizing enzymes and inhibiting tumor metastasis. (2) indirectly regulate FA metabolism by targeting the regulators and signaling pathways of FA metabolism.
With the rapid development of the medical and health industry today, the speed and depth of medical research have reached an unprecedented level. In-depth understanding of the mechanism of FA metabolism depends on large-scale clinical data, but in reality, the difficulty factor of sample acquisition is large, and the research results are stagnant due to the insufficient sample size, which cannot meet our current further research on FA metabolism.
At present, the types of targeted inhibitors of FA metabolic-related enzymes in the market are limited, which limits our in-depth understanding of FA metabolic-related diseases and the innovation of treatment methods. In order to fill this historical gap, it is particularly urgent to expand the research on targeted inhibitors. This includes not only the discovery of new inhibitors, but also the optimization and modification of existing inhibitors to improve their selectivity and effectiveness.
Cancer metastasis is a complex multi-step process, involving various links such as cell invasion, migration, angiogenesis, and infiltration and integration in a new environment. Which link has a potential connection with FA metabolism-related enzymes is a great challenge for current research work. Through the cellular and molecular biology research and large-scale genome and transcriptome analysis, can further understand the stage of cancer metastasis and the connection between the FA metabolism-related enzymes.
References
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394:1467–80.
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12–49.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
Bhandari A, Woodhouse M, Gupta S. Colorectal cancer is a leading cause of cancer incidence and mortality among adults younger than 50 years in the USA: a SEER-based analysis with comparison to other young-onset cancers. J Investig Med. 2017;65:311–15.
Sninsky JA, Shore BM, Lupu GV, Crockett SD. Risk factors for colorectal polyps and cancer. Gastrointest Endosc Clin N Am. 2022;32:195–213.
Baidoun F, Elshiwy K, Elkeraie Y, Merjaneh Z, Khoudari G, Sarmini MT, et al. Colorectal cancer epidemiology: recent trends and impact on outcomes. Curr Drug Targets. 2021;22:998–1009.
Zhang C, Zhang Y, Dong Y, Zi R, Wang Y, Chen Y, et al. Non-alcoholic fatty liver disease promotes liver metastasis of colorectal cancer via fatty acid synthase dependent EGFR palmitoylation. Cell Death Discov. 2024;10:41.
Chang L, Xu L, Tian Y, Liu Z, Song M, Li S, et al. NLRP6 deficiency suppresses colorectal cancer liver metastasis growth by modulating M-MDSC-induced immunosuppressive microenvironment. Biochim Biophys Acta Mol Basis Dis. 2024;1870:167035.
Galandiuk S, Wieand HS, Moertel CG, Cha SS, Fitzgibbons RJ Jr, Pemberton JH, et al. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet. 1992;174:27–32.
Weiss L, Grundmann E, Torhorst J, Hartveit F, Moberg I, Eder M, et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol. 1986;150:195–203.
Mitry E, Guiu B, Cosconea S, Jooste V, Faivre J, Bouvier AM. Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut. 2010;59:1383–8.
Rong D, Sun G, Zheng Z, Liu L, Chen X, Wu F, et al. MGP promotes CD8(+) T cell exhaustion by activating the NF-κB pathway leading to liver metastasis of colorectal cancer. Int J Biol Sci. 2022;18:2345–61.
Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325:669–85.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
Bergers G, Fendt SM. The metabolism of cancer cells during metastasis. Nat Rev Cancer. 2021;21:162–80.
Martin-Perez M, Urdiroz-Urricelqui U, Bigas C, Benitah SA. The role of lipids in cancer progression and metastasis. Cell Metab. 2022;34:1675–99.
German NJ, Yoon H, Yusuf RZ, Murphy JP, Finley LW, Laurent G, et al. PHD3 loss in cancer enables metabolic reliance on fatty acid oxidation via deactivation of ACC2. Mol Cell. 2016;63:1006–20.
Brown JC, Caan BJ, Prado CM, Cespedes Feliciano EM, Xiao J, Kroenke CH, et al. The association of abdominal adiposity with mortality in patients with stage I-III colorectal cancer. J Natl Cancer Inst. 2020;112:377–83.
Patel AV, Patel KS, Teras LR. Excess body fatness and cancer risk: a summary of the epidemiologic evidence. Surg Obes Relat Dis. 2023;19:742–45.
Lee CK, Jeong SH, Jang C, Bae H, Kim YH, Park I, et al. Tumor metastasis to lymph nodes requires YAP-dependent metabolic adaptation. Science. 2019;363:644–9.
Ell B, Kang Y. Transcriptional control of cancer metastasis. Trends Cell Biol. 2013;23:603–11.
Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011;17:1498–503.
Yu XH, Ren XH, Liang XH, Tang YL. Roles of fatty acid metabolism in tumourigenesis: beyond providing nutrition (Review). Mol Med Rep. 2018;18:5307–16.
Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in cancer. Br J Cancer. 2020;122:4–22.
de Carvalho C, Caramujo MJ. The various roles of fatty acids. Molecules. 2018;23:2583.
Korbecki J, Bosiacki M, Gutowska I, Chlubek D, Baranowska-Bosiacka I. Biosynthesis and significance of fatty acids, glycerophospholipids, and triacylglycerol in the processes of glioblastoma tumorigenesis. Cancers. 2023;15:2183.
Wang X, Zhang C, Bao N. Molecular mechanism of palmitic acid and its derivatives in tumor progression. Front Oncol. 2023;13:1224125.
Zhang J, Zhang L, Ye X, Chen L, Zhang L, Gao Y, et al. Characteristics of fatty acid distribution is associated with colorectal cancer prognosis. Prostaglandins Leukot Ess Fat Acids. 2013;88:355–60.
Santa-María C, López-Enríquez S, Montserrat-de la Paz S, Geniz I, Reyes-Quiroz ME, Moreno M, et al. Update on anti-inflammatory molecular mechanisms induced by oleic acid. Nutrients. 2023;15:224.
Shahidi F, Ambigaipalan P. Omega-3 polyunsaturated fatty acids and their health benefits. Annu Rev Food Sci Technol. 2018;9:345–81.
Fagone P, Jackowski S. Membrane phospholipid synthesis and endoplasmic reticulum function. J Lipid Res. 2009;50:S311–6.
Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis. 2016;5:e189.
Günenc AN, Graf B, Stark H, Chari A. Fatty acid synthase: structure, function, and regulation. Subcell Biochem. 2022;99:1–33.
Merino Salvador M, Gómez de Cedrón M, Moreno Rubio J, Falagán Martínez S, Sánchez Martínez R, Casado E, et al. Lipid metabolism and lung cancer. Crit Rev Oncol Hematol. 2017;112:31–40.
Yamada T, Oshima T, Yoshihara K, Tamura S, Kanazawa A, Inagaki D, et al. Overexpression of MMP-13 gene in colorectal cancer with liver metastasis. Anticancer Res. 2010;30:2693–9.
Verma RP, Hansch C. Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. Bioorg Med Chem. 2007;15:2223–68.
Buttacavoli M, Di Cara G, Roz E, Pucci-Minafra I, Feo S, Cancemi P. Integrated multi-omics investigations of metalloproteinases in colon cancer: focus on MMP2 and MMP9. Int J Mol Sci. 2021;22:12389.
Hu W, Wang Y, Zhang Q, Luo Q, Huang N, Chen R, et al. MicroRNA-199a-3p suppresses the invasion and metastasis of nasopharyngeal carcinoma through SCD1/PTEN/AKT signaling pathway. Cell Signal. 2023;110:110833.
Gao Y, Nan X, Shi X, Mu X, Liu B, Zhu H, et al. SREBP1 promotes the invasion of colorectal cancer accompanied upregulation of MMP7 expression and NF-kappaB pathway activation. BMC Cancer. 2019;19:685.
Fidler IJ. Angiogenesis and cancer metastasis. Cancer J. 2000;6:S134–41.
Viallard C, Larrivée B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis. 2017;20:409–26.
Alonso-Camino V, Santos-Valle P, Ispizua MC, Sanz L, Alvarez-Vallina L. Engineered human tumor xenografts with functional human vascular networks. Microvasc Res. 2011;81:18–25.
Li XF, O’Donoghue JA. Hypoxia in microscopic tumors. Cancer Lett. 2008;264:172–80.
Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 2011;17:1359–70.
Gao Y, Nan X, Shi X, Mu X, Liu B, Zhu H, et al. SREBP1 promotes the invasion of colorectal cancer accompanied upregulation of MMP7 expression and NF-κB pathway activation. BMC Cancer. 2019;19:685.
Manfioletti G, Fedele M. Epithelial-mesenchymal transition (EMT). Int J Mol Sci. 2023;24:11386.
Manfioletti G, Fedele M. Epithelial-mesenchymal transition (EMT) 2021. Int J Mol Sci. 2022;23:5848.
Azizan S, Cheng KJ, Mejia Mohamed EH, Ibrahim K, Faruqu FN, Vellasamy KM, et al. Insights into the molecular mechanisms and signalling pathways of epithelial to mesenchymal transition (EMT) in colorectal cancer: a systematic review and bioinformatic analysis of gene expression. Gene. 2024;896:148057.
Mohamed AH, Said NM. Immunohistochemical expression of fatty acid synthase and vascular endothelial growth factor in primary colorectal cancer: a clinicopathological study. J Gastrointest Cancer. 2019;50:485–92.
Tu K, Zheng X, Dou C, Li C, Yang W, Yao Y, et al. MicroRNA-130b promotes cell aggressiveness by inhibiting peroxisome proliferator-activated receptor gamma in human hepatocellular carcinoma. Int J Mol Sci. 2014;15:20486–99.
Quan J, Cheng C, Tan Y, Jiang N, Liao C, Liao W, et al. Acyl-CoA synthetase long-chain 3-mediated fatty acid oxidation is required for TGFβ1-induced epithelial-mesenchymal transition and metastasis of colorectal carcinoma. Int J Biol Sci. 2022;18:2484–96.
Auten RL, Davis JM. Oxygen toxicity and reactive oxygen species: the devil is in the details. Pediatr Res. 2009;66:121–7.
Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev. 2014;94:909–50.
Moloney JN, Cotter TG. ROS signalling in the biology of cancer. Semin Cell Dev Biol. 2018;80:50–64.
Zhao S, Cheng L, Shi Y, Li J, Yun Q, Yang H. MIEF2 reprograms lipid metabolism to drive progression of ovarian cancer through ROS/AKT/mTOR signaling pathway. Cell Death Dis. 2021;12:18.
Xiong J. Fatty acid oxidation in cell fate determination. Trends Biochem Sci. 2018;43:854–7.
Li XX, Wang ZJ, Zheng Y, Guan YF, Yang PB, Chen X, et al. Nuclear receptor Nur77 facilitates melanoma cell survival under metabolic stress by protecting fatty acid oxidation. Mol Cell. 2018;69:480–92.e7.
Svensson RU, Shaw RJ. Cancer metabolism: tumour friend or foe. Nature. 2012;485:590–1.
Jeon SM, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature. 2012;485:661–5.
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060–72.
Delesderrier E, Monteiro JDC, Freitas S, Pinheiro IC, Batista MS, Citelli M. Can iron and polyunsaturated fatty acid supplementation induce ferroptosis? Cell Physiol Biochem. 2023;57:24–41.
Lee JY, Nam M, Son HY, Hyun K, Jang SY, Kim JW, et al. Polyunsaturated fatty acid biosynthesis pathway determines ferroptosis sensitivity in gastric cancer. Proc Natl Acad Sci USA. 2020;117:32433–42.
Vriens K, Christen S, Parik S, Broekaert D, Yoshinaga K, Talebi A, et al. Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity. Nature. 2019;566:403–6.
Li C, Peng X, Lv J, Zou H, Liu J, Zhang K, et al. SREBP1 as a potential biomarker predicts levothyroxine efficacy of differentiated thyroid cancer. Biomed Pharmacother. 2020;123:109791.
Li W, Tai Y, Zhou J, Gu W, Bai Z, Zhou T, et al. Repression of endometrial tumor growth by targeting SREBP1 and lipogenesis. Cell Cycle. 2012;11:2348–58.
Xu H, Luo J, Ma G, Zhang X, Yao D, Li M, et al. Acyl-CoA synthetase short-chain family member 2 (ACSS2) is regulated by SREBP-1 and plays a role in fatty acid synthesis in caprine mammary epithelial cells. J Cell Physiol. 2018;233:1005–16.
Icard P, Wu Z, Fournel L, Coquerel A, Lincet H, Alifano M. ATP citrate lyase: a central metabolic enzyme in cancer. Cancer Lett. 2020;471:125–34.
Burke AC, Huff MW. ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia. Curr Opin Lipido. 2017;28:193–200.
Feng X, Zhang L, Xu S, Shen AZ. ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: an updated review. Prog Lipid Res. 2020;77:101006.
Wen J, Min X, Shen M, Hua Q, Han Y, Zhao L, et al. ACLY facilitates colon cancer cell metastasis by CTNNB1. J Exp Clin Cancer Res. 2019;38:401.
Zhang M, Peng R, Wang H, Yang Z, Zhang H, Zhang Y, et al. Nanog mediated by FAO/ACLY signaling induces cellular dormancy in colorectal cancer cells. Cell Death Dis. 2022;13:159.
Qiao C, Huang W, Chen J, Feng W, Zhang T, Wang Y, et al. IGF1-mediated HOXA13 overexpression promotes colorectal cancer metastasis through upregulating ACLY and IGF1R. Cell Death Dis. 2021;12:564.
Quan J, Bode AM, Luo X. ACSL family: the regulatory mechanisms and therapeutic implications in cancer. Eur J Pharm. 2021;909:174397.
Singh AB, Dong B, Xu Y, Zhang Y, Liu J. Identification of a novel function of hepatic long-chain acyl-CoA synthetase-1 (ACSL1) in bile acid synthesis and its regulation by bile acid-activated farnesoid X receptor. Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864:358–71.
Wang Y, Yu W, Li S, Guo D, He J, Wang Y. Acetyl-CoA carboxylases and diseases. Front Oncol. 2022;12:836058.
Padanad MS, Konstantinidou G, Venkateswaran N, Melegari M, Rindhe S, Mitsche M, et al. Fatty acid oxidation mediated by Acyl-CoA synthetase long chain 3 is required for mutant KRAS lung tumorigenesis. Cell Rep. 2016;16:1614–28.
Hardie DG, Pan DA. Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem Soc Trans. 2002;30:1064–70.
Zhang CY, Zhang R, Zhang L, Wang ZM, Sun HZ, Cui ZG, et al. Regenerating gene 4 promotes chemoresistance of colorectal cancer by affecting lipid droplet synthesis and assembly. World J Gastroenterol. 2023;29:5104–24.
Fhu CW, Ali A. Fatty acid synthase: an emerging target in cancer. Molecules. 2020;25:3935.
Singh K, Graf B, Linden A, Sautner V, Urlaub H, Tittmann K, et al. Discovery of a regulatory subunit of the yeast fatty acid synthase. Cell. 2020;180:1130–43.e20.
Richard C, Calder PC. Docosahexaenoic acid. Adv Nutr. 2016;7:1139–41.
Wu Y, Zhou Y, Gao H, Wang Y, Cheng Q, Jian S, et al. LYAR promotes colorectal cancer progression by upregulating FSCN1 expression and fatty acid metabolism. Oxid Med Cell Longev. 2021;2021:9979707.
Currie E, Schulze A, Zechner R, Walther TC, Farese RV Jr. Cellular fatty acid metabolism and cancer. Cell Metab. 2013;18:153–61.
ALJohani AM, Syed DN, Ntambi JM. Insights into stearoyl-CoA desaturase-1 regulation of systemic metabolism. Trends Endocrinol Metab. 2017;28:831–42.
Ran H, Zhu Y, Deng R, Zhang Q, Liu X, Feng M, et al. Stearoyl-CoA desaturase-1 promotes colorectal cancer metastasis in response to glucose by suppressing PTEN. J Exp Clin Cancer Res. 2018;37:54.
Liao C, Li M, Li X, Li N, Zhao X, Wang X, et al. Trichothecin inhibits invasion and metastasis of colon carcinoma associating with SCD-1-mediated metabolite alteration. Biochim Biophys Acta Mol Cell Biol Lipids. 2020;1865:158540.
Wu T, Wan J, Qu X, Xia K, Wang F, Zhang Z, et al. Nodal promotes colorectal cancer survival and metastasis through regulating SCD1-mediated ferroptosis resistance. Cell Death Dis. 2023;14:229.
Shu H, Peng Y, Hang W, Nie J, Zhou N, Wang DW. The role of CD36 in cardiovascular disease. Cardiovasc Res. 2022;118:115–29.
Liu ML, Zang F, Zhang SJ. RBCK1 contributes to chemoresistance and stemness in colorectal cancer (CRC). Biomed Pharmacother. 2019;118:109250.
Misbah M, Kumar M, Lee KH, Shen SC. Identification of novel miRNAs, targeting genes, signaling pathway, and the small molecule for overcoming oxaliplatin resistance of metastatic colorectal cancer. Biomed Res Int. 2022;2022:3825760.
Kuemmerle NB, Rysman E, Lombardo PS, Flanagan AJ, Lipe BC, Wells WA, et al. Lipoprotein lipase links dietary fat to solid tumor cell proliferation. Mol Cancer Ther. 2011;10:427–36.
Pepino MY, Kuda O, Samovski D, Abumrad NA. Structure-function of CD36 and importance of fatty acid signal transduction in fat metabolism. Annu Rev Nutr. 2014;34:281–303.
Drury J, Rychahou PG, Kelson CO, Geisen ME, Wu Y, He D, et al. Upregulation of CD36, a fatty acid translocase, promotes colorectal cancer metastasis by increasing MMP28 and decreasing E-cadherin expression. Cancers. 2022;14:252.
Amiri M, Yousefnia S, Seyed Forootan F, Peymani M, Ghaedi K, Nasr Esfahani MH. Diverse roles of fatty acid binding proteins (FABPs) in development and pathogenesis of cancers. Gene. 2018;676:171–83.
Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov. 2008;7:489–503.
Li B, Hao J, Zeng J, Sauter ER. SnapShot: FABP functions. Cell. 2020;182:1066–66.e1.
Zhang GL, Pan LL, Huang T, Wang JH. The transcriptome difference between colorectal tumor and normal tissues revealed by single-cell sequencing. J Cancer. 2019;10:5883–90.
Prayugo FB, Kao TJ, Anuraga G, Ta HDK, Chuang JY, Lin LC, et al. Expression profiles and prognostic value of FABPs in colorectal adenocarcinomas. Biomedicines. 2021;9:1460.
Zhang Y, Zhang W, Xia M, Xie Z, An F, Zhan Q, et al. High expression of FABP4 in colorectal cancer and its clinical significance. J Zhejiang Univ Sci B. 2021;22:136–45.
Montero-Calle A, Gómez de Cedrón M, Quijada-Freire A, Solís-Fernández G, López-Alonso V, Espinosa-Salinas I, et al. Metabolic reprogramming helps to define different metastatic tropisms in colorectal cancer. Front Oncol. 2022;12:903033.
Kawaguchi K, Ohashi T, Kobayashi N, Kanemoto K, Nose M, Shinozaki R, et al. Aberrant DNA methylation-mediated NF-κB/fatty acid-binding protein 5 (FABP5) feed-forward loop promotes malignancy of colorectal cancer cells. Biochim Biophys Acta Mol Cell Biol Lipids. 2023;1868:159362.
Brunmeir R, Xu F. Functional regulation of PPARs through post-translational modifications. Int J Mol Sci. 2018;19:1738.
Bougarne N, Weyers B, Desmet SJ, Deckers J, Ray DW, Staels B, et al. Molecular actions of PPARα in lipid metabolism and inflammation. Endocr Rev. 2018;39:760–802.
Luo Y, Xie C, Brocker CN, Fan J, Wu X, Feng L, et al. Intestinal PPARα protects against colon carcinogenesis via regulation of methyltransferases DNMT1 and PRMT6. Gastroenterology. 2019;157:744–59.e4.
Dai W, Xiang W, Han L, Yuan Z, Wang R, Ma Y, et al. PTPRO represses colorectal cancer tumorigenesis and progression by reprogramming fatty acid metabolism. Cancer Commun. 2022;42:848–67.
Wang D, Fu L, Wei J, Xiong Y, DuBois RN. PPARδ mediates the effect of dietary fat in promoting colorectal cancer metastasis. Cancer Res. 2019;79:4480–90.
Shao H, Mohamed EM, Xu GG, Waters M, Jing K, Ma Y, et al. Carnitine palmitoyltransferase 1A functions to repress FoxO transcription factors to allow cell cycle progression in ovarian cancer. Oncotarget. 2016;7:3832–46.
Casals N, Zammit V, Herrero L, Fadó R, Rodríguez-Rodríguez R, Serra D. Carnitine palmitoyltransferase 1C: from cognition to cancer. Prog Lipid Res. 2016;61:134–48.
Fang W, Cui H, Yu D, Chen Y, Wang J, Yu G. Increased expression of phospho-acetyl-CoA carboxylase protein is an independent prognostic factor for human gastric cancer without lymph node metastasis. Med Oncol. 2014;31:15.
Peng S, Chen D, Cai J, Yuan Z, Huang B, Li Y, et al. Enhancing cancer-associated fibroblast fatty acid catabolism within a metabolically challenging tumor microenvironment drives colon cancer peritoneal metastasis. Mol Oncol. 2021;15:1391–411.
Wang YN, Zeng ZL, Lu J, Wang Y, Liu ZX, He MM, et al. CPT1A-mediated fatty acid oxidation promotes colorectal cancer cell metastasis by inhibiting anoikis. Oncogene. 2018;37:6025–40.
Li J, Zheng W, Wu J, Zhang J, Lv B, Li W, et al. CPT1C-mediated fatty acid oxidation facilitates colorectal cancer cell proliferation and metastasis. Acta Biochim Biophys Sin. 2023;55:1301–9.
Guerrero-Zotano A, Mayer IA, Arteaga CL. PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev. 2016;35:515–24.
Tian W, Zhang W, Zhang Y, Zhu T, Hua Y, Li H, et al. FABP4 promotes invasion and metastasis of colon cancer by regulating fatty acid transport. Cancer Cell Int. 2020;20:512.
Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, et al. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022;7:3.
Zhang Y, Wang X. Targeting the Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol. 2020;13:165.
Yu F, Yu C, Li F, Zuo Y, Wang Y, Yao L, et al. Wnt/β-catenin signaling in cancers and targeted therapies. Signal Transduct Target Ther. 2021;6:307.
Wang H, Xi Q, Wu G. Fatty acid synthase regulates invasion and metastasis of colorectal cancer via Wnt signaling pathway. Cancer Med. 2016;5:1599–606.
Murata S, Yanagisawa K, Fukunaga K, Oda T, Kobayashi A, Sasaki R, et al. Fatty acid synthase inhibitor cerulenin suppresses liver metastasis of colon cancer in mice. Cancer Sci. 2010;101:1861–5.
Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12:861–74.
Niculae AM, Dobre M, Herlea V, Vasilescu F, Ceafalan LC, Trandafir B, et al. Lipid handling protein gene expression in colorectal cancer: CD36 and targeting miRNAs. Life. 2022;12:2127.
Peng Y, Xu C, Wen J, Zhang Y, Wang M, Liu X, et al. Fatty acid metabolism-related lncRNAs are potential biomarkers for predicting the overall survival of patients with colorectal cancer. Front Oncol. 2021;11:704038.
Yang Y, Luo D, Shao Y, Shan Z, Liu Q, Weng J, et al. circCAPRIN1 interacts with STAT2 to promote tumor progression and lipid synthesis via upregulating ACC1 expression in colorectal cancer. Cancer Commun. 2023;43:100–22.
Yuan M, Zhang X, Yue F, Zhang F, Jiang S, Zhou X, et al. CircNOLC1 Promotes colorectal cancer liver metastasis by interacting with AZGP1 and sponging miR-212-5p to regulate reprogramming of the oxidative pentose phosphate pathway. Adv Sci. 2023;10:e2205229.
Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y, Hu LL. ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 2020;19:1997–2007.
Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 2005;6:322–7.
Zhu J, Long T, Gao L, Zhong Y, Wang P, Wang X, et al. RPL21 interacts with LAMP3 to promote colorectal cancer invasion and metastasis by regulating focal adhesion formation. Cell Mol Biol Lett. 2023;28:31.
Wei J, Zheng Z, Hou X, Jia F, Yuan Y, Yuan F, et al. Echinacoside inhibits colorectal cancer metastasis via modulating the gut microbiota and suppressing the PI3K/AKT signaling pathway. J Ethnopharmacol. 2024;318:116866.
Hsiao YH, Chen NC, Koh YC, Nagabhushanam K, Ho CT, Pan MH. Pterostilbene inhibits adipocyte conditioned-medium-induced colorectal cancer cell migration through targeting FABP5-related signaling pathway. J Agric Food Chem. 2019;67:10321–9.
Wang C, Lan T, Chen Z, Wang X, Han Y, Yang N, et al. The preventive effects of inulin, cellulose, and their mixture on colorectal cancer liver metastasis in mice by regulating gut microbiota. J Food Sci. 2023;88:4705–17.
Ye X, Wu Y, Xu J, Liu H, Wang H, Li Q, et al. PPARβ mediates mangiferin-induced neuronal differentiation of neural stem cells through DNA demethylation. Pharm Res. 2022;179:106235.
Honari M, Shafabakhsh R, Reiter RJ, Mirzaei H, Asemi Z. Resveratrol is a promising agent for colorectal cancer prevention and treatment: focus on molecular mechanisms. Cancer Cell Int. 2019;19:180.
Song B, Wang W, Tang X, Goh RMW, Thuya WL, Ho PCL, et al. Inhibitory potential of resveratrol in cancer metastasis: from biology to therapy. Cancers. 2023;15:2758.
Acknowledgements
We want to express our gratitude for the drawing materials provided by Biorender. (https://www.biorender.com/).
Funding
This work was supported by Heilongjiang Provincial Natural Science Foundation of China (YQ2023H018), National Natural Science Foundation of China (82303285).
Author information
Authors and Affiliations
Contributions
Writing—original draft preparation, BL; writing—review and editing, BL, JM, and QY. All authors have read and agreed to the published version of the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Li, B., Mi, J. & Yuan, Q. Fatty acid metabolism-related enzymes in colorectal cancer metastasis: from biological function to molecular mechanism. Cell Death Discov. 10, 350 (2024). https://doi.org/10.1038/s41420-024-02126-9
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41420-024-02126-9
- Springer Nature Limited